PRIMECAP Odyssey Growth (POGRX)
46.45
+0.09 (+0.19%)
USD |
Jan 22
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 0.65% | 10.14B | 0.38% | 9.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -4.366B | 24.43% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide long-term capital appreciation. The fund invests primarily in the common stocks of U.S. companies, emphasizing those companies with the potential for above average earnings growth. It may invest in stocks across all market sectors and market capitalizations. Although it has historically invested primarily in large- and mid-capitalization companies, it has also invested a significant portion of its assets in small-capitalization stocks. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | POGRX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | US Equity |
| Broad Category | Equity |
| Category Name | Large Growth |
| Category Index | Russell 1000 Growth TR USD |
| Prospectus Objective | Growth |
| Fund Owner Firm Name | PRIMECAP Odyssey Funds |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Alfred Mordecai | 16.18 yrs |
| Joel Fried | 16.18 yrs |
| Theo Kolokotrones | 16.18 yrs |
| M. Ansari | 8.73 yrs |
| James Marchetti | 6.17 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
96
-4.366B
-18.65B
Category Low
17.04B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of December 31, 2020
Performance Versus Category
As of January 22, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of January 22, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly and Co | 3.30% | 206.14 | 1.87% |
| Alibaba Group Holding Ltd ADR | 3.21% | 258.62 | -0.53% |
| Abiomed Inc | 3.16% | 347.90 | -0.19% |
| Biogen Inc | 2.83% | 269.44 | -0.25% |
|
Seattle Genetics I
|
2.82% | -- | -- |
| Amgen Inc | 2.52% | 253.50 | 0.58% |
| Insulet Corp | 2.27% | 290.30 | -0.11% |
|
E*TRADE Financial Corp
|
2.22% | -- | -- |
| AECOM | 2.21% | 53.68 | 0.37% |
| BeiGene Ltd ADR | 2.15% | 374.50 | 4.90% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | Upgrade |
| Administration Fee | -- |
| Performance Fee | -- |
| Switching Fee | -- |
| Transaction Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
Basic Info
| Investment Strategy | |
| The investment seeks to provide long-term capital appreciation. The fund invests primarily in the common stocks of U.S. companies, emphasizing those companies with the potential for above average earnings growth. It may invest in stocks across all market sectors and market capitalizations. Although it has historically invested primarily in large- and mid-capitalization companies, it has also invested a significant portion of its assets in small-capitalization stocks. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | POGRX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | US Equity |
| Broad Category | Equity |
| Category Name | Large Growth |
| Category Index | Russell 1000 Growth TR USD |
| Prospectus Objective | Growth |
| Fund Owner Firm Name | PRIMECAP Odyssey Funds |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Alfred Mordecai | 16.18 yrs |
| Joel Fried | 16.18 yrs |
| Theo Kolokotrones | 16.18 yrs |
| M. Ansari | 8.73 yrs |
| James Marchetti | 6.17 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (1-22-21) | 0.38% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 24.66 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of September 30, 2020
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 11/1/2004 |
| Last Annual Report Date | 10/31/2020 |
| Last Prospectus Date | 2/28/2020 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |